In the study, ¿insulin pump-associated adverse events are common, but not associated with glycemic control, socioeconomic status, nor pump/ infusion set type¿, 174 adults and children within new zealand participated in a questionnaire examining pump-related issues they had experienced in the preceding 12 months.In table 1 of the article, the data shows that 22 of the 174 surveyed patients used medtronic insulin pumps.The 9 children and 13 adults on medtronic devices used a full spectrum of the products, ranging from the x54 veo insulin pumps to the paradigm series insulin pumps.The types of infusion sets used by the medtronic customers included the paradigm quick-set, paradigm silhouette, and paradigm mio.Of the 174 study participants (22 of which were using medtronic devices), 66 subjects reported device malfunctions including, mechanical/electronic malfunctions 31/66 (47%), physical damage 19/66 (29%), battery related 10/66 (15%), screen fade 10/66 (10%), keypad problems 6/66 (9%), water damage 5/66 (8%), leaking insulin 4/66 (6%), and lost/missing hardware 2/66 (3%).Infusion set/site related adverse events could also be further subcategorized in 41/74 subjects, with no additional information available in those remaining.In order of reported frequency: complete failure 17/41 (41%), infusion set damage 8/41 (20%), insertion failure 7/41 (17%), adhesive failure 6/41 (15%), pain 1/41 (2%), recurrent air bubbles 1/41 (2%), and obvious manufacturing fault prior to insertion 1/41 (2%).In a similar manner, all cutaneous adverse events were subcategorized, in order of reported frequency: skin irritation/reactions 54/74 (73%), scarring 36/74 (49%), infection 30/74 (41%), bleeding/bruising 4/74 (5%), lipohypertrophy 2/74 (3%), and lipoatrophy 1/74 (1%).An event serious enough to require a hospital presentation occurred in 9.8%, all but one reporting high ketones or diabetic ketoacidosis (dka).The article concludes that insulin pump-associated adverse events appear common and should therefore be anticipated.However, few variables are predictive of them with no relationships seen with glycaemic control, socioeconomic status, pump manufacturer nor infusion set type.Based on these findings, adverse events should be anticipated in both adults and children, with anticipatory patient education and training recommended for their successful and safe use.Individual events were not recorded in this study.No products were returned or replaced in response to these study results.
|